The Platform
KEMIRIX v1.0 — Clinical Decision SupportReimagined for the Real World
Our platform delivers unparalleled clinical intelligence directly to the point of care. Twelve distinct layers of clinical safety, integrated into one lightning-fast, offline-capable application — built for every facility from Nairobi to rural Kenya.
Drug Interaction Checker
Real-time screening with hard-gate veto logic.
KEMIRIX screens all co-administered medications simultaneously against multiple validated databases. When a severe interaction is detected, the system applies hard-gate veto logic that cannot be overridden by AI, ensuring dangerous combinations never slip through — at any facility, at any time.
Why This Matters in Africa
In environments where polypharmacy is common and patient records are fragmented, a non-overridable safety net is the difference between life and death. 125,000 people die annually from drug interactions in the US alone — in Africa, the true toll is unknown because the data does not exist.
Pharmacogenomics Engine
Africa's first embedded PGx engine.
Our platform accounts for G6PD A- variants, CYP2D6 polymorphisms, and over 50 African population-specific genetic factors that heavily influence drug metabolism and efficacy. Most CDS tools are calibrated on Western genomic datasets — KEMIRIX is built on African population frequencies.
Why This Matters in Africa
95% of patients carry actionable PGx variants, yet most clinical tools are based solely on Western genomic profiles. G6PD deficiency affects 15–25% of West Africans — prescribing without this awareness is clinically dangerous.
AI Diagnosis Support
Multi-layer clinical reasoning.
Drawing from an immense dataset of validated clinical symptoms and outcomes, our reasoning engine provides ranked differential diagnoses to assist clinicians in identifying rare or complex conditions quickly. Evidence-cited, explainable, and built to augment — not replace — the clinician.
Why This Matters in Africa
With a severe shortage of specialists in many regions, empowering primary care physicians with specialist-level AI support accelerates accurate treatment. The global diagnostic error rate of 10–15% represents preventable harm at massive scale.
Medical Imaging AI
Radiologist-grade interpretation for every clinic.
Integrated AI imaging analysis for chest X-rays, ECGs, and diabetic retinopathy screening — delivering specialist-level interpretation to any clinic with a camera or scanner. KEMIRIX's imaging module runs on-device, meaning it operates even without connectivity.
Why This Matters in Africa
50% of the global population has no access to a radiologist. In sub-Saharan Africa, there is approximately one radiologist per 1,000,000 people. AI imaging analysis is not a convenience — it is the only diagnostic option for millions of patients.
Traditional Medicine Integration
The only CDS platform with TM interaction data at scale.
KEMIRIX uniquely maps interactions between conventional pharmaceuticals and African traditional medicines, Ayurvedic preparations, and TCM compounds. Our traditional medicine database is continuously updated with peer-reviewed interaction data, giving clinicians the information they need about what their patients are actually taking.
Why This Matters in Africa
80% of Africans use traditional medicine alongside pharmaceuticals. Most clinical AI systems have zero data on traditional medicine interactions — creating a massive, invisible safety gap. KEMIRIX is the only platform built to close it.
Offline-First Architecture
Works from Nairobi to the most remote clinic on Earth.
KEMIRIX is architected offline-first — core clinical reasoning, drug interaction checking, and pharmacogenomics assessment all run locally on device with zero internet dependency. When connectivity is available, the platform synchronises with the cloud and updates its knowledge bases automatically.
Why This Matters in Africa
Internet connectivity is unreliable or absent across vast areas of sub-Saharan Africa. A CDS tool that requires connectivity is a CDS tool that fails rural patients. Offline-first is not a feature — it is a clinical ethics requirement.
Regulatory
Kenya PPB Category II SaMD — Our Regulatory Commitment
KEMIRIX is actively pursuing Kenya Pharmacy and Poisons Board (PPB) Category II Software as a Medical Device (SaMD) certification. Our regulatory strategy is aligned with international SaMD frameworks, ensuring that KEMIRIX is not just innovative but clinically validated and safe for human use at scale across Africa.